Speaker illustration

Mrs Andree Levorsen

(Norway)

Comparative effectiveness and costs of enoxaparin versus unfractionated heparin in treating acute coronary syndrome

Event: ESC Congress 2019

Topic: Pharmacotherapy

Session: Acute Coronary Syndromes - P2Y12 inhibitor

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb